India Pharma Outlook Team | Wednesday, 20 May 2026
HAB Pharma targets Rs 3,000 crore revenue by 2030 as the pharmaceutical company moves ahead with an ambitious expansion strategy following its merger with Signature Phytochemical Industries.
The deal marks a major step in HAB Pharma growth strategy, with the company aiming to strengthen manufacturing, enter specialty medicines segments, and expand its reach in global pharmaceutical markets over the next few years.
The merger has brought both companies under a single operational structure, creating a combined business with an estimated turnover of around Rs 600 crore after adjusting internal transactions. Company leaders believe the integration will improve efficiency, simplify operations, and create a stronger foundation for long-term growth in an increasingly competitive Indian pharmaceutical industry.
Also Read: Bayer Deepens India Self-Care Push Amid Rising Demand
HAB Pharma, established in 1980, has built a strong presence in pharmaceutical formulations, including antibiotics, cardiovascular medicines, and anti-inflammatory drugs. With manufacturing facilities in Mumbai and Dehradun, the company has steadily expanded its domestic and global presence over the years.
The addition of Signature Phytochemical Industries is expected to further strengthen pharmaceutical manufacturing capabilities. The merged business will now have greater flexibility across tablets, capsules, creams, and other formulations, helping the company meet rising demand more efficiently.
Going forward, HAB Pharma plans to focus on specialty therapies such as oncology, autoimmune diseases, chronic illnesses, and rare disorders. The company believes these areas offer strong long-term growth potential as healthcare demand rises globally. By investing in oncology medicines, complex formulations, and specialized therapies, HAB Pharma hopes to establish a stronger position in high-growth pharmaceutical categories.
Company officials say the merger is not only about increasing scale but also about improving innovation and speed. Combining research and development capabilities is expected to help the company bring medicines to market faster while maintaining quality and affordability through drug manufacturing expansion.
As part of its expansion roadmap, HAB Pharma is preparing to launch new manufacturing facilities, expected to begin commercial operations by August 2026. One facility will focus on sterile manufacturing, including semaglutide products, injectables, vials, and lyophilized medicines. The second plant will be a fully automated oral solid dosage facility designed to increase production efficiency.
The company is also looking beyond India to drive future growth. It plans to expand its presence in key international markets, including Latin America, Central Asia, and Southeast Asia, as part of a broader pharma export strategy. Expanding globally could help the company diversify revenue streams and reduce dependence on the domestic market.
Industry experts believe India’s pharmaceutical sector is entering a new phase of growth, especially in specialty drug manufacturing and advanced formulations. Companies investing in manufacturing expansion and research are expected to gain a competitive edge in both local and overseas markets.
For HAB Pharma, the merger represents more than a business integration—it signals a long-term commitment to becoming a larger player in the pharmaceutical sector. With stronger manufacturing capacity, wider product offerings, and a clear expansion roadmap, the company is positioning itself for sustained growth through pharma industry expansion.
.jpg)
.jpg)
